National Cancer Center

Eutilex Co., Ltd.

Eulji University Industry Academy Cooperation Foundation

Heon Yoo

Seung Hoon Lee

Seung-hoon Lee

Byoung S Kwon

Sang-Hoon Shin

Jin-Soo Lee

Young-Joo Lee

Kwang Gi Kim

Young-Woo Kim

Sang-Jae Park

Ho-Sik Oh

Don-Gil Lee

Beom-Kyu Choi

Kwang-Hui Kim

Sang-Yoon Park

Hyeon-Seok Eom

Hyun-Guy Kang

Byung-Kiu Park

Young-Ho Kim

Young Ho Kim

Young Tae Kim

Tae Hoon Kim

Jong Bae Park

Yung-Ho Jo

Heung-Ki Jeon

Seung-Hoon Lee

Hea Jin Kim

Donghee Lee

Eun Kyoung Park

Hee Jin Kwak

Jin Soo Lee

Ho-Shin Gwak

Byoung Se Kwon

The present invention provides a skull implant-type automatic fluid drain device comprising: a body having a first port to be connected to a catheter, a second port provided opposite the first port, and a flow passage connecting the first port and the second port; a separation member for separating the flow passage into first and second sub-channels; a first valve fixed to the separation member and provided to allow the movement of a fluid that moves from the first port to the second port in the first sub-channel; and a second valve fixed to the separation member and provided to allow the movement of a fluid that moves from the second port to the first port in the second sub-channel, wherein each of the first valve and the second valve has an inflow end portion that is open and a discharge end portion provided in a closed state such that the same is selectively opened at an allowed opening pressure or higher; each of the first valve and the second valve is configured such that the inner flow sectional area decreases along the direction of allowed movement of the fluid passing through each of the inflow end portion and the discharge end portion; and the allowed opening pressures of the first valve and the second valve are set to differ from each other.

Skull implant-type automatic fluid drain device

Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8T cells, and more particularly, a method for selecting an epitope recognized by CD8T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Methods for isolating and proliferating autologous cancer antigen-specific CD8T cells

Methods for isolating and proliferating autologous cancer antigen-specific CD8+T cells

A skull implant medication injection port comprises: a mounted portion placed on an upper section of a port insertion hole in a patient's cranium and a medication inlet on a top surface; a medication injection diaphragm that seals the medication inlet of the mounted portion where a needle for injecting a medication is inserted; a medication storage portion coupled with a bottom of the mounted portion stores the medication injected through the medication injection diaphragm; a medication discharge pipe connected to the medication storage portion discharges the medication stored in the medication storage portion; and a rib formed on a perimeter between the mounted portion and the medication storage portion that has a diameter larger than an inner diameter of the port insertion hole. A height of the mounted portion is generally about 4 to 7 mm, and a height of the medication storage portion is generally about 2 to 4.2 mm.

Skull implant type medication injection port

Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma.

Composition containing microRNA-21 inhibitor for enhancing radiation sensitivity

Disclosed herein is an apparatus for removing fine tumor cells, which remain around a treatment area of patient body, from which a tumor is eliminated, after surgery for removing the tumor has been conducted. The apparatus of the present invention includes a main body, which has a supply tube and a discharge tube that circulate liquid supplied from a storage tank, which is provided outside, and a therapeutic member, which is integrally coupled to an extension pipe that is coupled to the main body and surrounds the supply tube and the discharge tube. A cavity, which communicates with the supply tube and the discharge tube and is supplied with the liquid, is defined in the therapeutic member. The apparatus further includes a temperature sensing unit, which measures a temperature of a treatment area of a patient.

Apparatus for treating tumors

Growing community of inventors

Seoul, South Korea

Heon Yoo